Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Cash & Current Investments: 2010-2024

Historic Cash & Current Investments for China Pharma Holdings (CPHI) over the last 15 years, with Dec 2024 value amounting to $626,879.

  • China Pharma Holdings' Cash & Current Investments fell 58.26% to $300,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 million, marking a year-over-year decrease of 47.20%. This contributed to the annual value of $626,879 for FY2024, which is 55.97% down from last year.
  • Per China Pharma Holdings' latest filing, its Cash & Current Investments stood at $626,879 for FY2024, which was down 55.97% from $1.4 million recorded in FY2023.
  • Over the past 5 years, China Pharma Holdings' Cash & Current Investments peaked at $4.9 million during FY2021, and registered a low of $626,879 during FY2024.
  • Moreover, its 3-year median value for Cash & Current Investments was $1.4 million (2023), whereas its average is $1.4 million.
  • In the last 5 years, China Pharma Holdings' Cash & Current Investments soared by 407.39% in 2021 and then crashed by 58.22% in 2022.
  • Yearly analysis of 5 years shows China Pharma Holdings' Cash & Current Investments stood at $957,653 in 2020, then skyrocketed by 407.39% to $4.9 million in 2021, then tumbled by 58.22% to $2.0 million in 2022, then declined by 29.86% to $1.4 million in 2023, then crashed by 55.97% to $626,879 in 2024.